SCAI 2026 Building and Sustaining Your RDN Program-What Does RDN Data Look Like Post-Approval? Dr. Kobayashi

What Does RDN Data Look Like Post-Approval? Dr. Kobayashi

Video Transcription

Video Summary

The speaker urged renal denervation operators to focus on long-term outcomes, not just the short 2–6 month FDA approval data. He highlighted durable blood pressure reductions through 3–8 years for both radiofrequency and ultrasound technologies, and stressed setting patient expectations around delayed response. He also called for broader participation in CMS continuing evidence development registries to strengthen real-world evidence. This registry data, he argued, is essential for moving CPT codes from Category 3 to Category 1, which would improve national insurance coverage. The panel agreed that real-world, longitudinal data are critical for expanding access and validating renal denervation.

Asset Caption

closed captions are computer-generated

Keywords

renal denervation

long-term outcomes

blood pressure reduction

CMS registry

CPT code coverage